Skip to main content
Top
Published in: Heart and Vessels 3/2024

23-10-2023 | Heart Failure | Original Article

Soluble ST2, BCN-Bio-HF calculator and MAGGIC-HF score in long-term risk prediction after an urgent visit for heart failure

Authors: Teresa Miriam Pérez-Sanz, Itziar Gómez-Salvador, Pau Codina, Beatriz Calvo Antón, María Mar de la Torre Carpente, Belén Redondo Bermejo, Cristina Tapia Ballesteros

Published in: Heart and Vessels | Issue 3/2024

Login to get access

Abstract

Soluble ST2 (sST2) is the expression of a pathogenic process related to adverse remodeling that ultimately leads to increased mortality in heart failure (HF). Risk score models provide a comprehensive approach for mortality prediction, beyond the use of biomarkers alone. The objective was to determine the additional value of sST2 and two well-validated contemporary risk scores, BCN-Bio-HF and MAGGIC-HF, in predicting mortality and readmission in the acute setting. This prospective study included 129 patients (mean age 75 ± 9 years; 52% males) after an urgent HF visit. Baseline sST2 levels were measured and the two risk scores were calculated. The primary endpoint was all-cause mortality, and the secondary endpoint was HF readmissions. The follow-up period was 3.6 ± 1.9 years. Patients who died (46%) had higher sST2 concentrations (80.5 vs. 42.7 ng/ml; p < 0.001). The BCN-Bio-HF calculator with sST2 demonstrated the best discriminative ability for mortality prediction (area under the ROC curve: 0.792; p < 0.001). In multivariate analysis for each risk score, the MAGGIC-HF score retained its predictive value only in the model without sST2 (3-year risk: HR = 1.036; 95% CI 1.019–1.054; p < 0.001). However, the BCN-Bio-HF score maintained its prognostic value with sST2 (HR = 1.032; 95%CI 1.020–1.044; p < 0.001), as well as without sST2 (HR = 1.035; 95% CI 1.021–1.049; p < 0.001). sST2 was not associated with readmission, and only the BCN-Bio-HF risk of HF hospitalization showed independent predictive value (OR = 1.040; 95% CI 1.005–1.076; p = 0.023). For predicting long-term mortality in HF in the emergency department, the BCN-Bio-HF calculator with sST2 demonstrated superior discrimination and allows estimation of the risk of HF hospitalizations.
Literature
1.
go back to reference Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, Jaarsma T, Krum H, Rastogi V, Rohde LE, Samal UC, Shimokawa H, Budi Siswanto B, Sliwa K, Filippatos G (2014) Heart failure: preventing disease and death worldwide. ESC Heart Failure 1:4–25CrossRefPubMed Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, Jaarsma T, Krum H, Rastogi V, Rohde LE, Samal UC, Shimokawa H, Budi Siswanto B, Sliwa K, Filippatos G (2014) Heart failure: preventing disease and death worldwide. ESC Heart Failure 1:4–25CrossRefPubMed
2.
go back to reference Weintraub NL, Collins SP, Pang PS, Levy PD, Anderson AS, Arslanian-Engoren C, Gibler WB, McCord JK, Parshall MB, Francis GS, Gheorghiade M (2010) Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims. Circulation 122:1975–1996CrossRefPubMed Weintraub NL, Collins SP, Pang PS, Levy PD, Anderson AS, Arslanian-Engoren C, Gibler WB, McCord JK, Parshall MB, Francis GS, Gheorghiade M (2010) Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims. Circulation 122:1975–1996CrossRefPubMed
3.
go back to reference Meijers WC, Bayes-Genis A, Mebazaa A, Bauersachs J, Cleland JGF, Coats AJS, Januzzi JL, Maisel AS, McDonald K, Mueller T, Richards AM, Seferovic P, Mueller C, de Boer RA (2021) Circulating heart failure biomarkers beyond natriuretic peptides: review. Eur J Heart Fail 23:1610–1632CrossRefPubMed Meijers WC, Bayes-Genis A, Mebazaa A, Bauersachs J, Cleland JGF, Coats AJS, Januzzi JL, Maisel AS, McDonald K, Mueller T, Richards AM, Seferovic P, Mueller C, de Boer RA (2021) Circulating heart failure biomarkers beyond natriuretic peptides: review. Eur J Heart Fail 23:1610–1632CrossRefPubMed
4.
5.
go back to reference Pascual-Figal D, Januzzi JL (2015) The biology of ST2: the international ST2 consensus panel. Am J Cardiol 115:3B-7BCrossRefPubMed Pascual-Figal D, Januzzi JL (2015) The biology of ST2: the international ST2 consensus panel. Am J Cardiol 115:3B-7BCrossRefPubMed
6.
go back to reference Park S, Kim IC, Kim H, Cho YK, Lee CH, Hur SH (2022) Ability of soluble ST2 to predict left ventricular remodeling in patients with acute coronary syndrome. Heart Vessels 37:173–183CrossRefPubMed Park S, Kim IC, Kim H, Cho YK, Lee CH, Hur SH (2022) Ability of soluble ST2 to predict left ventricular remodeling in patients with acute coronary syndrome. Heart Vessels 37:173–183CrossRefPubMed
7.
go back to reference Alba AC, Agoritsas T, Jankowski M, Courvoisier D, Walter SD, Guyatt GH, Ross HJ (2013) Risk prediction models for mortality in ambulatory patients with heart failure: a systematic review. Circ Heart Fail 6:881–889CrossRefPubMed Alba AC, Agoritsas T, Jankowski M, Courvoisier D, Walter SD, Guyatt GH, Ross HJ (2013) Risk prediction models for mortality in ambulatory patients with heart failure: a systematic review. Circ Heart Fail 6:881–889CrossRefPubMed
8.
go back to reference Pocock SJ, Ariti CA, McMurray JJ, Maggioni A, Køber L, Squire IB, Swedberg K, Dobson J, Poppe KK, Whalley GA, Doughty RN (2013) Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J 34:1404–1413CrossRefPubMed Pocock SJ, Ariti CA, McMurray JJ, Maggioni A, Køber L, Squire IB, Swedberg K, Dobson J, Poppe KK, Whalley GA, Doughty RN (2013) Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J 34:1404–1413CrossRefPubMed
9.
go back to reference Canepa M, Fonseca C, Chioncel O, Laroche C, Crespo-Leiro MG, Coats AJS, Mebazaa A, Piepoli MF, Tavazzi L, Maggioni AP (2018) Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry. JACC Heart Fail 6:452–462CrossRefPubMed Canepa M, Fonseca C, Chioncel O, Laroche C, Crespo-Leiro MG, Coats AJS, Mebazaa A, Piepoli MF, Tavazzi L, Maggioni AP (2018) Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry. JACC Heart Fail 6:452–462CrossRefPubMed
10.
go back to reference Lupón J, de Antonio M, Vila J, Peñafiel J, Galán A, Zamora E, Urrutia A, Bayes-Genis A (2014) Development of a novel heart failure risk tool: the Barcelona Bio-Heart Failure risk calculator (BCN Bio-HF calculator). PLoS ONE 9:e85466ADSCrossRefPubMedPubMedCentral Lupón J, de Antonio M, Vila J, Peñafiel J, Galán A, Zamora E, Urrutia A, Bayes-Genis A (2014) Development of a novel heart failure risk tool: the Barcelona Bio-Heart Failure risk calculator (BCN Bio-HF calculator). PLoS ONE 9:e85466ADSCrossRefPubMedPubMedCentral
11.
go back to reference Codina P, Lupón J, Borrellas A, Spitaleri G, Cediel G, Domingo M, Simpson J, Levy WC, Santiago-Vacas E, Zamora E, Buchaca D, Subirana I, Santesmases J, Diez-Quevedo C, Troya MI, Boldo M, Altmir S, Alonso N, González B, Rivas C, Nuñez J, McMurray J, Bayes-Genis A (2021) Head-to-head comparison of contemporary heart failure risk scores. Eur J Heart Fail 23:2035–2044CrossRefPubMed Codina P, Lupón J, Borrellas A, Spitaleri G, Cediel G, Domingo M, Simpson J, Levy WC, Santiago-Vacas E, Zamora E, Buchaca D, Subirana I, Santesmases J, Diez-Quevedo C, Troya MI, Boldo M, Altmir S, Alonso N, González B, Rivas C, Nuñez J, McMurray J, Bayes-Genis A (2021) Head-to-head comparison of contemporary heart failure risk scores. Eur J Heart Fail 23:2035–2044CrossRefPubMed
12.
go back to reference Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 37:2129–2200CrossRefPubMed Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 37:2129–2200CrossRefPubMed
13.
go back to reference Dieplinger B, Egger M, Gegenhuber A, Haltmayer M, Mueller T (2015) Analytical and clinical evaluation of a rapid quantitative lateral flow immunoassay for measurement of soluble ST2 in human plasma. Clin Chim Acta 451:310–315CrossRefPubMed Dieplinger B, Egger M, Gegenhuber A, Haltmayer M, Mueller T (2015) Analytical and clinical evaluation of a rapid quantitative lateral flow immunoassay for measurement of soluble ST2 in human plasma. Clin Chim Acta 451:310–315CrossRefPubMed
14.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRefPubMed Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRefPubMed
15.
16.
go back to reference Januzzi JL, Peacock WF, Maisel AS, Chae CU, Jesse RL, Baggish AL, O´Donoghue M, Sakhuja R, Chen AA, van Kimmenade RR, Lewandrowsky KB, Lloyd-Jones DM, Wu AH (2007) Measurement of the interleukin family member ST2 in patients with acute dyspnea: Results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 50:607–613CrossRefPubMed Januzzi JL, Peacock WF, Maisel AS, Chae CU, Jesse RL, Baggish AL, O´Donoghue M, Sakhuja R, Chen AA, van Kimmenade RR, Lewandrowsky KB, Lloyd-Jones DM, Wu AH (2007) Measurement of the interleukin family member ST2 in patients with acute dyspnea: Results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 50:607–613CrossRefPubMed
17.
go back to reference Emdin M, Aimo A, Vergaro G, Bayes-Genis A, Lupón J, Latini R, Meessen J, Anand IS, Cohn JN, Gravning J, Gullestad L, Broch K, Ueland T, Nymo SH, Brunner-La Rocca HP, de Boer RA, Gaggin HK, Ripoli A, Passino C, Januzzi JL Jr (2018) sST2 predicts outcome in chronic heart failure beyond NT-proBNP and high-sensitivity troponin T. J Am Coll Cardiol 72:2309–2320CrossRefPubMed Emdin M, Aimo A, Vergaro G, Bayes-Genis A, Lupón J, Latini R, Meessen J, Anand IS, Cohn JN, Gravning J, Gullestad L, Broch K, Ueland T, Nymo SH, Brunner-La Rocca HP, de Boer RA, Gaggin HK, Ripoli A, Passino C, Januzzi JL Jr (2018) sST2 predicts outcome in chronic heart failure beyond NT-proBNP and high-sensitivity troponin T. J Am Coll Cardiol 72:2309–2320CrossRefPubMed
18.
go back to reference van Vark LC, Lesman-Leegte I, Baart SJ, Postmus D, Pinto YM, Orsel JG, Westenbrink BD, Brunner-la Roca HP, van Mitenburg AJM, Boersma E, Hillege HL, Akkerhuis AJ (2017) Prognostic value of serial ST2 measurements in patients with acute heart failure. J Am Coll Cardiol 70:2378–2388CrossRefPubMed van Vark LC, Lesman-Leegte I, Baart SJ, Postmus D, Pinto YM, Orsel JG, Westenbrink BD, Brunner-la Roca HP, van Mitenburg AJM, Boersma E, Hillege HL, Akkerhuis AJ (2017) Prognostic value of serial ST2 measurements in patients with acute heart failure. J Am Coll Cardiol 70:2378–2388CrossRefPubMed
19.
go back to reference Yancy CW, Jessup M, Bozkurt B, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C (2017) 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure. J Am Coll Cardiol 70:776–803CrossRefPubMed Yancy CW, Jessup M, Bozkurt B, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C (2017) 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure. J Am Coll Cardiol 70:776–803CrossRefPubMed
20.
go back to reference McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Piepoli MF, Price S, Rosano GMC, Ruschitzka F, Skibelund AK (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599–3726CrossRefPubMed McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Piepoli MF, Price S, Rosano GMC, Ruschitzka F, Skibelund AK (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599–3726CrossRefPubMed
21.
go back to reference Aimo A, Vergaro G, Ripoli A, Bayes-Genis A, Pascual Figal DA, de Boer RA, Lassus J, Mebazaa A, Gayat E, Breidthardt T, Sabti Z, Mueller C, Brunner-La Rocca HP, Tang WH, Grodin JL, Zhang Y, Bettencourt P, Maisel AS, Passino C, Januzzi JL, Emdin M (2017) Meta-analysis of soluble suppression of tumorigenicity-2 and prognosis in acute heart failure. JACC Heart Fail 5:287–296CrossRefPubMed Aimo A, Vergaro G, Ripoli A, Bayes-Genis A, Pascual Figal DA, de Boer RA, Lassus J, Mebazaa A, Gayat E, Breidthardt T, Sabti Z, Mueller C, Brunner-La Rocca HP, Tang WH, Grodin JL, Zhang Y, Bettencourt P, Maisel AS, Passino C, Januzzi JL, Emdin M (2017) Meta-analysis of soluble suppression of tumorigenicity-2 and prognosis in acute heart failure. JACC Heart Fail 5:287–296CrossRefPubMed
22.
go back to reference Berg DD, Jhund PS, Docherty KF, Murphy SA, Verma S, Inzucchi SE, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sjöstrand M, Solomon SD, McMurray JJV, Sabatine MS (2021) Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction. JAMA Cardiol 6:499–507CrossRefPubMedPubMedCentral Berg DD, Jhund PS, Docherty KF, Murphy SA, Verma S, Inzucchi SE, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sjöstrand M, Solomon SD, McMurray JJV, Sabatine MS (2021) Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction. JAMA Cardiol 6:499–507CrossRefPubMedPubMedCentral
23.
go back to reference Tomasoni D, Adamo M, Anker MS, von Haehling S, Coats AJS, Metra M (2020) Heart failure in the last year: progress and perspective. ESC Heart Fail 7:3505–3530CrossRefPubMedPubMedCentral Tomasoni D, Adamo M, Anker MS, von Haehling S, Coats AJS, Metra M (2020) Heart failure in the last year: progress and perspective. ESC Heart Fail 7:3505–3530CrossRefPubMedPubMedCentral
24.
go back to reference Codina P, Zamora E, Bayes-Genis A (2023) Reply to “The frail patient and the frailing heart.” Eur J Heart Fail 25:441–442CrossRefPubMed Codina P, Zamora E, Bayes-Genis A (2023) Reply to “The frail patient and the frailing heart.” Eur J Heart Fail 25:441–442CrossRefPubMed
25.
go back to reference Wessman T, Tofik R, Ruge T, Melander O (2022) Associations between biomarkers of multimorbidity burden and mortality risk among patients with acute dyspnea. Intern Emerg Med 17:559–567CrossRefPubMed Wessman T, Tofik R, Ruge T, Melander O (2022) Associations between biomarkers of multimorbidity burden and mortality risk among patients with acute dyspnea. Intern Emerg Med 17:559–567CrossRefPubMed
26.
go back to reference Setoguchi S, Stevenson LW, Schneeweiss S (2007) Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J 154:260–266CrossRefPubMed Setoguchi S, Stevenson LW, Schneeweiss S (2007) Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J 154:260–266CrossRefPubMed
27.
go back to reference Anand IS, Rector TS, Kuskowski M, Snider J, Cohn JN (2014) Prognostic value of soluble ST2 in the valsartan heart failure trial. Circ Heart Fail 7:418–426CrossRefPubMed Anand IS, Rector TS, Kuskowski M, Snider J, Cohn JN (2014) Prognostic value of soluble ST2 in the valsartan heart failure trial. Circ Heart Fail 7:418–426CrossRefPubMed
28.
go back to reference Böhm M, Komajda M, Borer JS, Ford I, Maack C, Tavazzi L, Moyne A, Swedberg K (2018) Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. Eur J Heart Fail 20:373–381CrossRefPubMed Böhm M, Komajda M, Borer JS, Ford I, Maack C, Tavazzi L, Moyne A, Swedberg K (2018) Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. Eur J Heart Fail 20:373–381CrossRefPubMed
29.
go back to reference Núñez J, de la Espriella R, Rossignol P, Voors AA, Mullens W, Metra M, Chioncel O, Januzzi JL, Mueller C, Richards AM, de Boer RA, Thum T, Arfsten H, González A, Abdelhamid M, Adamopoulos S, Anker SD, Gal TB, Biegus J, Cohen-Solal A, Böhm M, Emdin M, Jankowska EA, Gustafsson F, Hill L, Jaarsma T, Jhund PS, Lopatin Y, Lund LH, Milicic D, Moura B, Piepoli MF, Ponikowski P, Rakisheva A, Ristic A, Savarese G, Tocchetti CG, Van Linthout S, Volterrani M, Seferovic P, Rosano G, Coats AJS, Bayes-Genis A (2022) Congestion in heart failure: a circulating biomarker-based perspective. A review from the biomarkers working group of the heart failure association, european society of cardiology. Eur J Heart Fail 24:1751–1766CrossRefPubMed Núñez J, de la Espriella R, Rossignol P, Voors AA, Mullens W, Metra M, Chioncel O, Januzzi JL, Mueller C, Richards AM, de Boer RA, Thum T, Arfsten H, González A, Abdelhamid M, Adamopoulos S, Anker SD, Gal TB, Biegus J, Cohen-Solal A, Böhm M, Emdin M, Jankowska EA, Gustafsson F, Hill L, Jaarsma T, Jhund PS, Lopatin Y, Lund LH, Milicic D, Moura B, Piepoli MF, Ponikowski P, Rakisheva A, Ristic A, Savarese G, Tocchetti CG, Van Linthout S, Volterrani M, Seferovic P, Rosano G, Coats AJS, Bayes-Genis A (2022) Congestion in heart failure: a circulating biomarker-based perspective. A review from the biomarkers working group of the heart failure association, european society of cardiology. Eur J Heart Fail 24:1751–1766CrossRefPubMed
Metadata
Title
Soluble ST2, BCN-Bio-HF calculator and MAGGIC-HF score in long-term risk prediction after an urgent visit for heart failure
Authors
Teresa Miriam Pérez-Sanz
Itziar Gómez-Salvador
Pau Codina
Beatriz Calvo Antón
María Mar de la Torre Carpente
Belén Redondo Bermejo
Cristina Tapia Ballesteros
Publication date
23-10-2023
Publisher
Springer Japan
Keyword
Heart Failure
Published in
Heart and Vessels / Issue 3/2024
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-023-02327-9

Other articles of this Issue 3/2024

Heart and Vessels 3/2024 Go to the issue